Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $1.1 million.

  • Allogene Therapeutics' Change in Accured Expenses fell 57.04% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $478,000, marking a year-over-year increase of 112.40%. This contributed to the annual value of -$1.3 million for FY2024, which is 81.50% up from last year.
  • Per Allogene Therapeutics' latest filing, its Change in Accured Expenses stood at $1.1 million for Q3 2025, which was down 37.41% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Allogene Therapeutics' Change in Accured Expenses peaked at $8.9 million during Q3 2021, and registered a low of -$12.7 million during Q3 2023.
  • Over the past 3 years, Allogene Therapeutics' median Change in Accured Expenses value was $286,000 (recorded in 2023), while the average stood at -$953,364.
  • Data for Allogene Therapeutics' Change in Accured Expenses shows a peak YoY increase of 906.99% (in 2024) and a maximum YoY decrease of 1,140.51% (in 2024) over the last 5 years.
  • Over the past 5 years, Allogene Therapeutics' Change in Accured Expenses (Quarterly) stood at -$2.8 million in 2021, then soared by 213.33% to $3.1 million in 2022, then tumbled by 90.88% to $286,000 in 2023, then soared by 906.99% to $2.9 million in 2024, then tumbled by 57.04% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.7 million for Q2 2025, and -$5.2 million during Q1 2025.